Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Significant Benefit Of Nivolumab Treating PD-L1 Positive Metastatic Pulmonary Carcinosarcoma: A Case Report And Literature Review

Z. Zhang, Yishan Chen, Mingxia Ma, Junli Hao, R. Ding, Lixin Han, J. Zou, L. Zhang, Qin Meng, X. Qu, Y. Liu, M. Zhao
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Immunotherapy has recently become a new focus for the treatment of malignant tumors following the surgery, chemotherapy, radiotherapy, and molecular targeted therapy. Nivolumab, a human monoclonal antibody, is the first programmed cell death protein-1 (PD-1) inhibitor, which can prohibit the interaction of its ligand (PD-L1), restoring the immune response of T cells, and enhancing the recognition of tumor cells by the immune system. Pulmonary carcinosarcoma is an uncommon but highly aggressive tumor type with a poor prognosis. We described a case of pulmonary carcinosarcoma, with the positive expression of PD-L1, obtained a significant benefit from Nivolumab treatment in a 64-year-old Chinese man, which give us a clue that patients with pulmonary carcinosarcoma may benefit fromanti-PD-1 immunotherapy.



Semantic Scholar Logo Some data provided by SemanticScholar